Article
Oncology
Iwona Kwiecien, Elzbieta Rutkowska, Malgorzata Polubiec-Kownacka, Agata Raniszewska, Piotr Rzepecki, Joanna Domagala-Kulawik
Summary: This study investigated the expression of PD-L2 and PD-L1 on AMs in BALF of lung cancer patients, finding that AMs in clBALF were positive for PD-L1 and PD-L2, and the proportion of PD-1+ T lymphocytes was higher in clBALF compared to hlBALF and PB. The study discussed the potential of exploring the PD-1-PD-L1/PD-L2 pathway in lung cancer environment.
TRANSLATIONAL LUNG CANCER RESEARCH
(2021)
Article
Immunology
B. Leticia Rodriguez, Limo Chen, Yanli Li, Shucheng Miao, David H. Peng, Jared J. Fradette, Lixia Diao, Jessica M. Konen, Frank R. Rojas Alvarez, Luisa M. Solis, Xiaohui Yi, Aparna Padhye, Laura A. Gibson, Joshua K. Ochieng, Xiaofei Zhou, Jing Wang, Don L. Gibbons
Summary: The resistance to immune checkpoint blockade (ICB) therapy in non-small cell lung cancer (NSCLC) is associated with infiltrating monocytes, and controlling the differentiation process of monocytes can enhance the therapeutic potential of ICB.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Oncology
Prachi Bhave, Tasnia Ahmed, Serigne N. Lo, Alexander Shoushtari, Anne Zaremba, Judith M. Versluis, Joanna Mangana, Michael Weichenthal, Lu Si, Thierry Lesimple, Caroline Robert, Claudia Trojanello, Alexandre Wicky, Richard Heywood, Lena Tran, Kathleen Batty, Florentia Dimitriou, Anna Stansfeld, Clara Allayous, Julia K. Schwarze, Meghan J. Mooradian, Oliver Klein, Inderjit Mehmi, Rachel Roberts-Thomson, Andrea Maurichi, Hui-Ling Yeoh, Adnan Khattak, Lisa Zimmer, Christian U. Blank, Egle Ramelyte, Katharina C. Kaehler, Severine Roy, Paolo A. Ascierto, Olivier Michielin, Paul C. Lorigan, Douglas B. Johnson, Ruth Plummer, Celeste Lebbe, Bart Neyns, Ryan Sullivan, Omid Hamid, Mario Santinami, Grant A. McArthur, Andrew M. Haydon, Georgina Long, Alexander M. Menzies, Matteo S. Carlino
Summary: Acral melanoma is a rare subtype with poor prognosis, and there is a lack of prospective clinical trial evidence on the efficacy of checkpoint inhibitors in this population. The study found that initial anti-PD-1/ipilimumab combination had a significantly higher ORR compared to anti-PD-1 alone, but this benefit did not translate to improved OS in this retrospective cohort. Primary site did not impact treatment outcomes.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Review
Pharmacology & Pharmacy
Ze Xiang, Jiayuan Li, Zhengyu Zhang, Chao Cen, Wei Chen, Bin Jiang, Yiling Meng, Ying Wang, Bjoern Berglund, Guanghua Zhai, Jian Wu
Summary: Immunotherapy with immune checkpoint inhibitor (ICI) drugs is a hot topic in cancer treatment. Our study used Bayesian model to comprehensively evaluate the safety and efficacy of ICI drugs. Different ICI drug therapies may have different risks in terms of progression-free survival (PFS), overall survival (OS) and severe adverse events (AEs). Treatment with cemiplimab was found to be the best choice in terms of PFS and OS. Our study provides new insights and strategies for the clinical practice of ICI drugs.
FRONTIERS IN PHARMACOLOGY
(2022)
Review
Pharmacology & Pharmacy
Yuqian Feng, Huimin Jin, Kaibo Guo, Yuying Xiang, Yiting Zhang, Wurong Du, Minhe Shen, Shanming Ruan
Summary: The study supports the efficacy of combination therapy with immune checkpoint inhibitors (ICIs) in cancer treatment, especially showing longer PFS in patients with high PD-L1 expression. More high-quality clinical randomized controlled trials are needed in the future to confirm these findings, as the number of included trials was limited.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Oncology
Yasuhiro Nakamura, Kenjiro Namikawa, Yukiko Kiniwa, Hiroshi Kato, Osamu Yamasaki, Shusuke Yoshikawa, Takeo Maekawa, Shigeto Matsushita, Tatsuya Takenouchi, Takashi Inozume, Yasuo Nakai, Satoshi Fukushima, Shintaro Saito, Atsushi Otsuka, Noriki Fujimoto, Taiki Isei, Natsuki Baba, Taisuke Matsuya, Ryo Tanaka, Takahide Kaneko, Masazumi Onishi, Yutaka Kuwatsuka, Kotaro Nagase, Takehiro Onuma, Motoo Nomura, Yoshiyasu Umeda, Naoya Yamazaki
Summary: This study compared the efficacy of PD-1 and PD-1+CTLA-4 for the treatment of advanced AM in Japanese patients. The results showed no significant differences in ORR, PFS, and OS between the two groups in PSM patients. In NAM patients, the PD-1+CTLA-4 group had significantly higher ORR and longer PFS, and PD-1+CTLA-4 was identified as an independent predictor of favorable PFS in NAM patients.
EUROPEAN JOURNAL OF CANCER
(2022)
Article
Oncology
Hikmat H. Assi, Chihunt Wong, Kimberly A. Tipton, Li Mei, Ken Wong, Jennifer Razo, Chanty Chan, Bruce Howng, Jason Sagert, Michael Krimm, Linnea Diep, Andrew Jang, Margaret T. Nguyen, Nicole Lapuyade, Victoria Singson, Ruth Villanueva, Madan Paidhungat, Shouchun Liu, Vangipuram Rangan, Olga Vasiljeva, James W. West, Jennifer H. Richardson, Bryan Irving, Dylan Daniel, Marcia Belvin, W. Michael Kavanaugh
Summary: Using protease-activatable antibody prodrugs (Pb-Tx) to locally inhibit PD-1/PD-L1 can reduce systemic immune toxicity while eliciting potent anti-tumor immune responses.
CANCER IMMUNOLOGY RESEARCH
(2021)
Review
Biotechnology & Applied Microbiology
Selina K. Wong, Kathryn E. Beckermann, Douglas B. Johnson, Satya Das
Summary: This article explores the combination therapy of anti-CTLA-4 and anti-PD-1 antibodies in advanced malignancies, discussing the biological rationale, treatment schedules, toxicity profiles, and potential for use in different disease settings. It also anticipates the shift towards this combination therapy becoming a standard treatment for cancer patients.
EXPERT OPINION ON BIOLOGICAL THERAPY
(2021)
Review
Immunology
Huizhen Cao, Tianyu Wu, Xue Zhou, Shuyang Xie, Hongfang Sun, Yunxiao Sun, Youjie Li
Summary: Leukemia cells induce immunosuppression of the bone marrow microenvironment, preventing the immune system from clearing tumor cells. The PD-1/PD-L1 axis acts as a significant mechanism for tumor cells to evade immune surveillance. The development of drugs targeting PD-1/PD-L1 in leukemia is still at the clinical-trial stage.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Pharmacology & Pharmacy
Taisuke Kaiho, Hidemi Suzuki, Atsushi Hata, Hiroki Matsumoto, Kazuhisa Tanaka, Yuichi Sakairi, Shinichiro Motohashi, Ichiro Yoshino
Summary: Immune checkpoint molecules, such as PD-1 and PD-L1, have been shown to be important in lung cancer treatment. This study explored the role of these proteins in acute rejection in a mouse model of tracheal transplantation and found that PD-L1 Fc recombinant protein could decrease inflammatory cytokines and reduce the proportion of CD4+ T cells, suggesting a potential novel target for immunotherapy in lung transplantation.
FRONTIERS IN PHARMACOLOGY
(2023)
Article
Chemistry, Medicinal
Pratibha Pandey, Fahad Khan, Huda A. Qari, Tarun Kumar Upadhyay, Abdulhameed F. Alkhateeb, Mohammad Oves
Summary: Immunotherapy has made significant progress in cancer treatment through blocking immunological checkpoint pathways. Recent studies have shown that combining immune checkpoint inhibitors with other anticancer drugs can improve their effectiveness. Immune checkpoint blockade also aids in inhibiting angiogenesis and enhancing the immune system's efficacy.
Review
Immunology
Zena N. Willsmore, Ben G. T. Coumbe, Silvia Crescioli, Sara Reci, Ayushi Gupta, Robert J. Harris, Alicia Chenoweth, Jitesh Chauhan, Heather J. Bax, Alexa McCraw, Anthony Cheung, Gabriel Osborn, Ricarda M. Hoffmann, Mano Nakamura, Roman Laddach, Jenny L. C. Geh, Alastair MacKenzie-Ross, Ciaran Healy, Sophia Tsoka, James F. Spicer, Debra H. Josephs, Sophie Papa, Katie E. Lacy, Sophia N. Karagiannis
Summary: CTLA-4 and PD-1 are immune checkpoint molecules that are targets of antibody immunotherapies for malignant melanoma. Combination therapy with immune checkpoint inhibitors may have better outcomes compared to monotherapy in certain patient groups, but also presents challenges and increased rates of adverse events.
EUROPEAN JOURNAL OF IMMUNOLOGY
(2021)
Review
Oncology
Chia-Jung Li, Li-Te Lin, Ming-Feng Hou, Pei-Yi Chu
Summary: Significant progress has been made in understanding the role of PD-L1 in breast cancer, especially in TNBC. Early clinical trials of PD-L1/PD-1 inhibitors have shown efficacy in refractory metastatic breast cancer patients, particularly in TNBC. Mechanisms and factors influencing the immunoediting process have been summarized and analyzed in detail.
Review
Oncology
Chao Cheng, Lingdun Zhuge, Xin Xiao, Siyuan Luan, Yong Yuan
Summary: As the predominant treatment option for advanced esophageal cancer, PD-1 and PD-L1 inhibitors provide new hope to clinical practice. However, some patients do not respond to this therapy and most initially sensitive patients eventually develop resistance. Therefore, it is critical to understand the mechanisms of resistance and explore efficient strategies to overcome it, in order to expand the benefit of immunotherapy.
FRONTIERS IN ONCOLOGY
(2022)
Review
Oncology
Pushpamali De Silva, Marco Aiello, Chunyan Gu-Trantien, Edoardo Migliori, Karen Willard-Gallo, Cinzia Solinas
Summary: Immunotherapy approaches targeting immune checkpoint molecules like CTLA-4 have revolutionized treatment of solid tumors and hematological malignancies by enhancing antitumor immune responses. However, the use of anti-CTLA-4 Abs may lead to autoimmune-like adverse events, though this higher incidence is associated with improved clinical benefit.
INTERNATIONAL JOURNAL OF CANCER
(2021)
Meeting Abstract
Oncology
J. Domagala-Kulawik, A. Raniszewska, E. Rutkowska, R. Sokolowski, J. Bednarek, I. Kwiecien
ANNALS OF ONCOLOGY
(2022)
Meeting Abstract
Oncology
A. Raniszewska, I. Kwiecien, E. Rutkowska, R. Sokolowski, J. Bednarek, P. Rzepecki, J. Domagala-Kulawik
ANNALS OF ONCOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Mariusz Z. Ratajczak, Mateusz Adamiak, Andrzej Deptala, Joanna Domagala-Kulawik, Janina Ratajczak, Magdalena Kucia
Summary: This article discusses the induction of a sterile inflammation state through the activation of bone marrow stromal and innate immunity cells, which promotes the migration and engraftment of HSPCs. Deciphering these mechanisms will help in understanding the mechanisms of hematopoietic recovery after transplantation, and provide important information for optimizing the clinical process using small molecular modifiers of innate immunity and purinergic signaling.
ANTIOXIDANTS & REDOX SIGNALING
(2022)
Article
Oncology
Iwona Kwiecien, Elzbieta Rutkowska, Agata Raniszewska, Rafal Sokolowski, Joanna Bednarek, Karina Jahnz-Rozyk, Piotr Rzepecki, Joanna Domagala-Kulawik
Summary: The study found that in patients with lung cancer, the percentage of dendritic cells (DCs) in metastatic lymph nodes and peripheral blood was higher, and the proportion of DCs expressing PD-1, PD-L1, and CD80 was also higher in metastatic lymph nodes. Additionally, a higher proportion of regulatory DCs (DCregs) was found in metastatic lymph nodes.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2022)
Article
Virology
Elzbieta Rutkowska, Iwona Kwiecien, Krzysztof Klos, Piotr Rzepecki, Andrzej Chcialowski
Summary: This study aimed to analyze the differences in monocyte subpopulations between COVID-19 patients and convalescent patients. The results showed that COVID-19 patients had lower numbers and proportions of monocytes compared to convalescent patients, but higher proportions of PDL-1-positive intermediate monocytes. Additionally, COVID-19 patients had higher levels of PD-L1 and CD62L expression on monocytes.
Article
Immunology
Iwona Kwiecien, Elzbieta Rutkowska, Rafal Sokolowski, Joanna Bednarek, Agata Raniszewska, Karina Jahnz-Rozyk, Piotr Rzepecki, Joanna Domagala-Kulawik
Summary: In this study, we found that metastatic lymph nodes in lung cancer patients had a higher percentage of CD4+ and CD8+ effector memory T cells, as well as CD45RO+ T regulatory cells. Flow cytometry of lymph node samples obtained through EBUS/TBNA can be used to evaluate lymphocyte subsets and may reflect the immune status in lung cancer.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Medicine, General & Internal
Tomasz Skirecki, Barbara Adamik, Claes Frostell, Urszula Paslawska, Stanislaw Zielinski, Natalia Glatzel-Plucinska, Mateusz Olbromski, Piotr Dziegiel, Waldemar Gozdzik
Summary: This study investigated the effects of iNO and steroid treatment on monocyte subsets in a porcine model of endotoxemia. The results showed decreased SLA-DR expression and increased mitochondrial membrane potential in specific subsets of monocytes. The study also highlighted the importance of studying tissue-resident cells in addition to circulating counterparts.
JOURNAL OF CLINICAL MEDICINE
(2022)
Review
Oncology
Izabela Orzolek, Jan Sobieraj, Joanna Domagala-Kulawik
Summary: This review presents the current understanding of sex hormones in the development of malignant diseases, with a focus on the role of estrogens in modifying the immune response to cancer. Sex hormones have diverse effects on the immune system and play a role in various physiological and pathological pathways.
Article
Medicine, General & Internal
Malgorzata Gajewska, Elzbieta Rutkowska, Iwona Kwiecien, Piotr Rzepecki, Kazimierz Sulek
Summary: AgNOR parameter analysis is a valuable method for differentiating between adult AML and ALL.
Review
Oncology
Robert Ulinski, Iwona Kwiecien, Joanna Domagala-Kulawik
Summary: Chronic obstructive pulmonary disease (COPD) is an independent risk factor for lung cancer, and both diseases share similarities in immunopathogenesis. Some elements of autoimmunity may be involved in the development of emphysema and its relation with malignant transformation. COPD complicates lung cancer diagnosis and treatment, and tobacco smoking remains the main cause of these tobacco-dependent diseases.
Article
Oncology
Iwona Kwiecien, Elzbieta Rutkowska, Krzysztof Gawronski, Katarzyna Kulik, Alicja Dudzik, Agata Zakrzewska, Agata Raniszewska, Waldemar Sawicki, Piotr Rzepecki
Summary: This study aimed to assess the importance of new hematological parameters in patients with myelodysplastic syndrome (MDS), including those with and without cytogenetic changes. The study found that patients with cytogenetic changes had higher proportions of new neutrophil parameters compared to those without cytogenetic changes. The NE-FSC parameter was lower in patients with cytogenetic changes.
Article
Psychiatry
Pawel Kwiecien, Joanna Domagala-Kulawik
Summary: Obesity is a leading preventable cause of death worldwide and is associated with various diseases. Risk factors for obesity vary, including genetic background, physical activity, sleep quality, diet, and sociological and environmental aspects. Psychological factors, especially personality traits, also play a significant role in the development and persistence of obesity.
PSYCHIATRIA I PSYCHOLOGIA KLINICZNA-JOURNAL OF PSYCHIATRY AND CLINICAL PSYCHOLOGY
(2023)
Article
Biochemistry & Molecular Biology
Elzbieta Rutkowska, Iwona Kwiecien, Ewa Pietruszka-Waleka, Ewa Wiesik-Szewczyk, Piotr Rzepecki, Karina Jahnz-Rozyk
Summary: The study analyzed leukocyte subpopulations in COVID-19 patients at different time points and observed significant differences between severe and non-severe patients. The findings are valuable for the initial evaluation of the immune status of COVID-19 patients.